by Marija | May 2, 2023 | CML-CAB
11 June 2023, Frankfurt (Germany) – hybrid meeting:2nd Academic CML-CABA cure for CML beyond TFR: is it possible? Chronic myeloid leukemia (CML) is a hematological cancer that has become a chronic disease for most patients thanks to the current Tyrosine Kinase...
by CML Advocates | Aug 7, 2022 | CML-CAB
CML Community Advisory Board (CML-CAB) Meeting 2021 On 18 February 2021, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, hosted it´s first meeting of the year. It was the 12th CML Community Advisory Board (CML-CAB) and 22nd...
by CML Advocates | Jul 29, 2022 | CML-CAB
CML-CAB Meetings: Based on the proven ECAB model implemented by the HIV patient community and EATG for morethan a decade, the first CML-CAB was held in May 2016. Since then, we have carried out 12 CMLCABs in 22 sessions (2016-2021). 12 CML-CABs in 22 sessions from...
by CML Advocates | Jul 29, 2022 | CML-CAB
CML-CAB Objectives & Strategy The CML-CAB objectives are: Providing researchers, academics, government, policy makers, authorities and the pharmaceutical industry with advice and input on different issues that impact on patients’ lives Promoting...
by Marija | Jul 29, 2022 | CML-CAB
Composition of CML-CAB It falls within the responsibility of the CML-CAB chairs to determine how many and which members from the CML-CAB member pool (and potentially others) will be invited to specific CAB-meetings. The CML-CAB chairs will select participants based on...
by Marija | Jul 29, 2022 | CML-CAB
How do CABs work? CML-CAB invites participants from the companies CML-CAB sets the agenda for a two-way dialogue and pick the topics that are most meaningful to us CML-CAB respects confidentiality to have a trusted and open dialogue CML-CAB reports to...